Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients

Table 1 Demographic data and clinical data of the eight patients

Patient	Gender	Age at study onset	Disease duration	Previous treatment	EDSS at baseline	EDSS after 12 months	Relapses during first 12 months	cMRI at follow-up
MS1	Female	41	0	None	1.5	1.5	0	-
MS2	Female	50	10	None	1.5	1.5	1	New lesion
MS3	Female	37	33	IFN-beta sc.	1.0	1.5	0	stable
MS4	Female	38	9	None	1.0	1.5	0	New lesion
MS5	Female	38	89	IFN-beta sc.	3.5	2.0	1	stable
MS6	Female	47	1	None	1.5	1.5	0	New lesion
MS7	Male	35	16	None	1.0	1.0	0	New lesion
MS8	Male	25	55	Mitoxantrone	2.0	2.5	1	New lesion

The table shows gender, age, the previous treatment, and the EDSS scores at therapy initiation (baseline) and after 12 months. The duration from the diagnosis of definite MS to the start of GA therapy in months (disease duration) is also given. The gender ratio was 6:2 (female: male) and the average age at study onset was 38.9 ± 7.6 years (mean ± SD). Three patients had a relapse during the first 12 months after GA treatment initiation. Five patients showed a new brain lesion in the follow-up compared to pre-treatment. cMRI: cranial magnetic resonance imaging, EDSS: expanded disability status scale, sc.: subcutaneous, SD: standard deviation.

ISSN: 1742-2094